Literature DB >> 32215675

Outcome of simultaneous thulium laser enucleation of bladder tumor and prostate in patients with non-muscle invasive bladder tumor and benign prostatic hyperplasia: a matched-pair comparison with a long-term follow-up.

Yubin Wang1,2, Zhiling Zhang3, Jinkai Shao2, Yongan Lü2, Xiaodong Li2, Rongshan Li4.   

Abstract

OBJECTIVE: To access the surgical and oncological outcomes of simultaneous thulium laser enucleation of bladder tumor (ThuLEBT) and thulium laser enucleation of prostate (ThuLEP) in patients with non-muscle invasive bladder tumor (NMIBC) and benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: Between June 2009 and June 2017, 118 men with NMIBC who underwent simultaneous ThuLEBT and ThuLEP and fulfilled the inclusion criteria were matched with 118 patients who received ThuLEBT alone. Clinicopathological parameters, surgical outcome data and oncological outcomes were retrospectively analyzed and compared.
RESULTS: The patients who underwent simultaneous ThuLEBT and ThuLEP experienced a longer length of operation time (70.4 vs. 25.5 min; p < 0.001), but there were no statistically significant differences in catheterization period, hospital stay and complication between the two groups. At a mean follow-up of 58.7 and 55.8 months in ThuLEBT/ThuLEP group and ThuLEBT group, no significant differences in overall recurrence rates, progression rates, recurrence in the bladder neck/prostatic fossa and mean elapsed time to recurrence were detected. The 5-year recurrence-free probability was 73.2% for ThuLEBT/ThuLEP and 69.2% for ThuLEBT (p = 0.361).
CONCLUSIONS: Our results indicate that simultaneous ThuLEBT and ThuLEP can be safely performed without increasing the surgical risk and the risk of tumor recurrence and progression in patients with NMIBC and BPH, and it may be preferred alternative for select patients.

Entities:  

Keywords:  Benign prostatic hyperplasia; Bladder tumor; Laser therapy; Thulium laser enucleation of bladder tumor; Thulium laser enucleation of prostate; Tumor recurrence

Mesh:

Substances:

Year:  2020        PMID: 32215675     DOI: 10.1007/s00345-020-03158-3

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  2 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project.

Authors:  Charles Welliver; Lydia Feinstein; Julia B Ward; Chyng-Wen Fwu; Ziya Kirkali; Tamara Bavendam; Brian R Matlaga; Kevin T McVary
Journal:  J Urol       Date:  2019-08-20       Impact factor: 7.450

  2 in total
  1 in total

Review 1.  The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.

Authors:  Reza Sari Motlagh; Keiichiro Mori; Noriyoshi Miura; Fahad Quhal; Abdulmajeed Aydh; Ekaterina Laukhtina; Benjamin Pradere; Pierre I Karakiewicz; Dmitry V Enikeev; Marina Deuker; Shahrokh F Shariat
Journal:  BJU Int       Date:  2020-08-12       Impact factor: 5.588

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.